RAREUltragenyx Pharmaceutical Inc.
Price
-45%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality strong, hard red flags, growing in the filings, the market against it.
We are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. We have built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. We were founded in April 2010 by our President and Chief Executive Officer, Emil Kakkis, M.D., Ph.D., and are led by a management team experienced in the development and commercialization of rare disease therapeutics.
In the company’s own words · 10-K filed Feb 18, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Ultragenyx Pharmaceutical Inc. (RARE) reported revenue of $214M in Q2 2026 (quarter ended Jun 30, 2026), up 28% from the same quarter a year earlier. That came with net loss of $92M. For the full year FY2025, revenue was $673M (+20% year on year) and net income −$575M. Its largest region in Q2 2026 was North America at $121M, 68% of the disclosed total, well ahead of Latin America at 28%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 7, 2026On October 6, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) to the buyer.Material agreement entered · Form 8-K
- Sep 17, 2026On September 17, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, for the treatment of pediatric patients with mucopolysaccharidosis …Other event · Form 8-K
- Sep 2, 2026On September 2, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $179.0MThe company’s own SEC segment disclosure.
- North America$121.0M68%
- Latin America$51.0M28%
- Asia Pacific$7.0M4%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.